AstraZeneca: Heartburn trials

The registry lists 24 Heartburn studies with AstraZeneca as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 1Phase 2 3Phase 3 3Phase 4 12No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving RabeprazoleCompletedNCT01397084Phase 4Results posted
• Efficacy of Esomeprazole in Patients With Frequent HeartburnCompletedNCT01370538Phase 3Results posted
• Efficacy of Esomeprazole in Patients With Frequent HeartburnCompletedNCT01370525Phase 3Results posted
• To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving RabeprazoleCompletedNCT01249651Phase 4Results posted
• Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPICompletedNCT01005251Phase 2Results posted
• A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)CompletedNCT00734097Phase 4Results posted
• Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) SymptomsCompletedNCT00703534Phase 2Results posted
• Symptom Improvements in Gastroesophageal Reflux Disease (GERD) PatientsCompletedNCT00394472Phase 2Results posted
• Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)CompletedNCT00842387
• Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.CompletedNCT00786773
• Uric Acid Study in Healthy Male VolunteersCompletedNCT00738842Phase 1
• Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been HealedCompletedNCT00644735Phase 4
• A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive EsophagitisCompletedNCT00641602Phase 4
• Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)CompletedNCT00637845Phase 4
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)CompletedNCT00628342Phase 4
• A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using PatientsCompletedNCT00625274Phase 4
• What is the Predictive Value of the Reflux Impact ScaleTerminatedNCT00536328
• Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERDCompletedNCT00524355
• Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI DamageCompletedNCT00524329
• Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERDCompletedNCT00410592Phase 4
• PPI Sequencing StudyCompletedNCT00384592Phase 4
• PPI Test in GP PatientsCompletedNCT00318084Phase 4
• HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related DiseaseCompletedNCT00243724Phase 3
• Acid-Associated Heartburn Symptoms and Dose of EsomeprazoleCompletedNCT00206024Phase 4